NSE: CARERATING | BSE: 534804

Mid-range Performer

Download real time

1577.10 -15.80 (-0.99%)

60.33% Gain from 52W Low

13,588 NSE+BSE Volume

NSE 19 Sep, 2025 1:40 PM (IST)

4,730.5

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

CARE Ratings Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CARERATING, BSE:534804 CARE Ratings Ltd.

CARE Ratings Ltd.

31 Jan 2018

1577.10

-0.99%

Credit Analysis & Research Ltd.

Buy: CARE Ratings Ltd.

ICICI Securities Limited

CARE's revenues were slightly above estimates but the bottomline was below estimate owing to lower other income & higher staff cost Reported rating revenues increased at a healthy rate of 14.2% YoY to | 74.8 crore. The QoQ decline of 18% in rating revenue was owing to surveillance fee income from Q2. There was an 18.2% YoY increase in volume of fresh debt rated in Q3FY18 to | 3.25 lakh crore. In that, volume of bank loan ratings increased 12.1% YoY However, PAT came in at | 37.3 crore (down 2% YoY) vs. estimate of...

CARE Ratings Ltd. is trading above its 200 day SMA of 1458.5

CARE Ratings Ltd.

16 Nov 2017

1577.10

-0.99%

CARE

Hold: CARE Ratings Ltd.

Centrum Broking

We retain Hold on Credit Analysis And Research (CARE) with TP at Rs1,560 (vs. earlier TP at Rs1,600). Q2'18 reported revenue was a tad higher to our estimates and follows the change in accounting policy towards surveillance related income recognition. Margins, though saw some moderation and we expect trend therein to continue. H2'18 promises to be better than H1'18 and is given the favourable regulatory framework its likely impact on the rating revenues for the credit rating agencies (CRA's). CARE with its strong business model and respectable market share remains one of the key beneficiaries. While we remain positive on CARE,...

CARE Ratings Ltd. has gained 43.82% in the last 6 Months

CARE Ratings Ltd.

16 Nov 2017

1577.10

-0.99%

Credit Analysis & Research Ltd.

Buy: CARE Ratings Ltd.

ICICI Securities Limited

PAT came in largely in line at | 48.3 crore (up 11.8% YoY). PAT margins were at 53.1% in Q2FY18 The company declared an interim dividend of | 6 per share. For,...

CARE Ratings Ltd. is trading above its 200 day SMA of 1458.5

CARE Ratings Ltd.

17 May 2017

1577.10

-0.99%

Credit Analysis & Research Ltd.

Buy: CARE Ratings Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Reported rating revenues were at | 76.4 crore (up 2% YoY). This was on account of slower growth in volume of rated debt, which increased 7.7% YoY and lower surveillance fee in Q4 Other income traction stayed strong and was in line at | 8.4 crore, up 2.4x YoY. This higher increase was due to redemption of liquid investment schemes and maturity of FMPs EBITDA came in at | 47 crore while the EBIDTA margin was at 61.7%...

Number of FII/FPI investors increased from 113 to 130 in Jun 2025 qtr.

CARE Ratings Ltd.

09 Feb 2017

1577.10

-0.99%

Result Update Q3FY17Credit Analysis and Research Ltd

Buy: CARE Ratings Ltd.

Religare

CARE Q3FY17 standalone earnings performance surprised positively on account of higher other income on FMP profit booking (Rs 16cr) and strong EBITDA margins. Revenues clocked in Rs 66cr (up 4.8% YoY), while reported PAT stood at Rs 45cr (up 68% YoY). The rating industry's healthy long-term prospects, strong visibility due to RBI measures to deepen the bond market and CARE's sustained earnings performance keep us positive on the stock.

CARE Ratings Ltd. is trading below its 30 day SMA of 1609.0

CARE Ratings Ltd.

06 Feb 2017

1577.10

-0.99%

Credit Analysis & Research Ltd.

Buy: CARE Ratings Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Reported rating revenues were at | 65.9 crore (up 5.1% YoY). For 9MFY17, rating revenues were up 7.8% YoY. This was on account of an increase in both volume of fresh debt rated and surveillance exercises carried out during the period Other income in Q3FY17 surprised positively and was at | 16.3 crore (I-direct estimate: | 4.5 crore) vs. <| 3 crore seen in the last several quarters. This was due to profit booked on maturity of certain...

CARE Ratings Ltd. has an average target of 1973.00 from 1 broker.

CARE Ratings Ltd.

03 Feb 2017

1577.10

-0.99%

EXCEL CROP CARE LTD

Buy: CARE Ratings Ltd.

Rudra Shares and Stock Brokers Ltd

With this acquisition, Excel crop would benefit in near term as global players are looking at India to increase their market share, add to their product portfolio, and strengthen their supply base in specialty and agrochemicals. Additionally, as a part of the strategic direction, it has decided to focus on speciality chemicals, pharma intermediates, pharma actives, performance chemicals and environment and biotech products as a primary focus for its future activities. Combining of ECCL's strong manufacturing capabilities along with SCC's world class research capabilities will take the company to greater heights. In addition to the company, Indian farmers will also stand benefited due to access to world renowned technologies and products and would lead...

CARE Ratings Ltd. has gained 43.82% in the last 6 Months

CARE Ratings Ltd.

23 Dec 2016

1577.10

-0.99%

Religare Investment Call - Credit Analysis and Research

Buy: CARE Ratings Ltd.

Religare

Credit Analysis and Research Ltd (CARE) is in the business of analysing and giving financial ratings to companies based on their financial health. Apart from this, it rates debt and bond instruments floated by various institutions. It is the second largest rating agency in India in terms of rating revenue.

CARE Ratings Ltd. is trading above its 200 day SMA of 1458.5

CARE Ratings Ltd.

07 Nov 2016

1577.10

-0.99%

Credit Analysis & Research Ltd.

Buy: CARE Ratings Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Rating revenues were at | 81 crore (up 4% YoY) in Q2FY17. For H1FY17, rating revenues were up 9.2% YoY. This was on account of...

Number of FII/FPI investors increased from 113 to 130 in Jun 2025 qtr.

CARE Ratings Ltd.

03 Oct 2016

1577.10

-0.99%

Management Call Update: BUY With a Target Price of Rs 1944, which is a 34% UPSIDE from the CMP of Rs 1450

Buy: CARE Ratings Ltd.

Ventura

We recently conducted a call with the management of Credit Research & Analysis Ltd. (CARE Ratings), the second largest rating agency in India. Since the past two years, the topline growth of the company has been muted, i.e., in the range of 7-10%. This was largely due to a slowing economy, which halted the capex cycle, adversely impacting credit issuances. However, with the government's renewed thrust on the infrastructure sector, coupled with a...

CARE Ratings Ltd. has gained 43.82% in the last 6 Months

Is CARE Ratings Ltd. worth buying?

175 Votes:

Buy 72.0%

Sell 18.29%

Hold 9.71%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Not Rated SEE REPORTS >

pdf